|
Dextrometorphan-quinidine for the treatment of pseudobulbar affect |
González L, García Martí S, Pichon-Riviere A, Augustovski F, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation González L, García Martí S, Pichon-Riviere A, Augustovski F, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L. Dextrometorphan-quinidine for the treatment of pseudobulbar affect. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rapida No. 492. 2016 Authors' conclusions Evidence of moderate quality shows that short-term use of dextrometorphan/quinidine would reduce the severity and number of weekly uncontrollable outbursts of laughing/crying in patients with pseudobulbar affect and diagnosed amyotrophic lateral sclerosis or multiple sclerosis when compared to placebo.
Low-quality evidence suggests that its use would also benefit patients with pseudobulbar affect secondary to dementia, traumatic brain injury and stroke.
The clinical practice guidelines that mention it, recommend it as a treatment option; it is covered by some United States health sponsors.
Final publication URL www.iecs.org.ar Indexing Status Subject indexing assigned by CRD MeSH Dextromethorphan; Humans; Pseudobulbar Palsy; Quinidine Language Published Spanish Country of organisation Argentina English summary An English language summary is available. Address for correspondence Institute for Clinical Effectiveness and Health Policy, Viamonte 2146 - 3 Piso, C1056ABH Ciudad de Buenos Aires, Argentina Tel: +54 11 49 66 00 82 Fax:+54 11 49 53 40 58 Email: info@iecs.org.ar AccessionNumber 32016001112 Date abstract record published 25/11/2016 |
|
|
|